Market Place
Sourcing Support
All News #Library
Others
BlueRock phase I trial for Parkinson’s disease continues to show positive trends
06 Mar 2024 //
PRESS RELEASE
Bayer-owned BlueRock cuts 12% of staff as pipeline contracts
17 Aug 2023 //
FIERCE BIOTECH
BlueRock Therapeutics & bit.bio announce collaboration for Treg based therapies
03 Aug 2023 //
PR NEWSWIRE
Bayer`s BlueRock taps Rune Labs for Parkinson`s study software
16 Mar 2023 //
FIERCE BIOTECH
BioCardia with BlueRock to Provide Catheter Biotherapeutic Delivery Candidates
24 Aug 2022 //
GLOBENEWSWIRE
New Berlin site to accelerate cell therapy innovation for BlueRock Therapeutics
14 Jun 2022 //
EUROPEANPHARMACEUTICALREVIEW
BlueRock Completes Enrollment of PI Trial in Parkinson`s Disease
31 May 2022 //
PRNEWSWIRE
Bayer`s VC arm making `Leaps` via `fewer, but maybe bigger bets`
22 Jan 2022 //
FIERCEBIOTECH
BlueRock Begins Dosing in Canada in Phase 1 Trial in Parkinson`s Disease
18 Jan 2022 //
PRNEWSWIRE
BlueRock: closeout of first cohort in phase 1 trial in Parkinson’s disease
08 Jan 2022 //
PHARMABIZ
J&J science chief Stoffels latest exec to exit—Chutes & Ladders
15 Oct 2021 //
FIERCEBIOTECH
Ensoma nabs Bayer`s $1B Parkinson`s head Nuwaysir for gene meds
12 Oct 2021 //
FIERCEBIOTECH
BlueRock Therapeutics Announces New Board Chair, New President and CEO
26 Jul 2021 //
PRNEWSWIRE
Bayer’s BlueRock Therapeutics gains FDA fast track for PD cell therapy
20 Jul 2021 //
PM LIVE
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01
19 Jul 2021 //
PR NEWSWIRE
Bayer studies cell and gene therapies for Parkinson’s disease
10 Jun 2021 //
CLINICAL TRAILS ARENA
Bayer subsidiary doses first patient with Parkinson’s disease cell therapy
10 Jun 2021 //
PHARMATIMES
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.